Patent: 10,675,328
✉ Email this page to a colleague
Summary for Patent: 10,675,328
Title: | Compositions and methods for treatment of Gcase related disease states |
Abstract: | Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin .alpha.4.beta.1, Very Late Antigen-4 positive neural precursor cell (\"VLA4+ NPC\") transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson\'s disease (PD), Dementia with Lewy bodies. |
Inventor(s): | Sun; Ying (Mason, OH) |
Assignee: | Children\'s Hospital Medical Center (Cincinnati, OH) |
Application Number: | 15/896,423 |
Patent Claims: | see list of patent claims |
Details for Patent 10,675,328
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | 05/23/1994 | ⤷ Try a Trial | 2037-02-14 |
Genzyme Corporation | CEREZYME | imiglucerase | For Injection | 020367 | 09/22/1999 | ⤷ Try a Trial | 2037-02-14 |
Takeda Pharmaceuticals U.s.a., Inc. | VPRIV | velaglucerase alfa | For Injection | 022575 | 02/26/2010 | ⤷ Try a Trial | 2037-02-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |